An exopolysaccharide from Trichoderma pseudokoningii and its apoptotic activity on human leukemia K562 cells

► An exopolysaccharide (EPS) was isolated from culture medium of Trichoderma species. ► EPS has anticancer activity in a time- and concentration- dependent manner. ► EPS induced human leukemia K562 cell apoptosis by the mitochondrial pathways. ► EPS has a potential application as an adjuvant therapy...

Full description

Saved in:
Bibliographic Details
Published inCarbohydrate polymers Vol. 89; no. 2; pp. 701 - 708
Main Authors Huang, Taotao, Lin, Jun, Cao, Jianfeng, Zhang, Pengying, Bai, Yungui, Chen, Guochuang, Chen, Kaoshan
Format Journal Article
LanguageEnglish
Published Kidlington Elsevier Ltd 20.06.2012
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:► An exopolysaccharide (EPS) was isolated from culture medium of Trichoderma species. ► EPS has anticancer activity in a time- and concentration- dependent manner. ► EPS induced human leukemia K562 cell apoptosis by the mitochondrial pathways. ► EPS has a potential application as an adjuvant therapy agent against human leukemia. In this study, a novel exopolysaccharide (EPS) was isolated from the fermentation broth of Trichoderma pseudokoningii and its anticancer activities on human leukemia K562 cells were studied. EPS could significantly inhibited K562 cells proliferation in a time- and concentration-dependent manner. Meanwhile, characteristic of apoptosis, including apoptotic morphological features and the apoptosis rate were obtained. Sequentially, the dissipation of mitochondrial membrane potential, increase production of Reactive oxygen species (ROS), enhancement of the concentration of intracellular, up-regulation of Bax and p53 mRNA, down-regulation of Bcl-2 mRNA were also detected. The results indicate that the EPS could induce of K562 cells apoptosis, primarily in involved the mitochondrial pathways. The present studies suggest that EPS could be a new potential adjuvant chemotherapeutic and chemo preventive agent against human leukemia.
Bibliography:http://dx.doi.org/10.1016/j.carbpol.2012.03.079
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0144-8617
1879-1344
DOI:10.1016/j.carbpol.2012.03.079